ClinicalTrials.gg
CompletedNCT00377520Updated Nov 20, 2009Results posted

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

A Phase 2 interventional study of pemetrexed in Neoplasms, Neoplasms by Site and Urogenital Neoplasms, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2009-11-20.

Primary conditionEndometrial NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Endometrial Neoplasms
Why
  1. The study's listed conditions name Endometrial Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Endometrial Neoplasms by Eli Lilly and Company — 4 open to participants now, 8 under way, none of them phase 3. Endometrial Neoplasms · Eli Lilly and Company.

Enrollment
10th of 10
27 · median 400
Started
2006
the only one that year
Phase 2
2 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Endometrial Neoplasms by Eli Lilly and Company, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2006, is one of 2 in phase 2, and was the 3rd registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 11 studies in Endometrial Neoplasms by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Endometrial Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.

03

Conditions studied

  • Neoplasms
  • Neoplasms by Site
  • Urogenital Neoplasms
  • Genital Neoplasms, Female
  • Uterine Neoplasms
  • Endometrial Neoplasms
  • Cancer of Endometrium
  • Endometrial Cancer
  • Cancer of the Endometrium
  • Endometrium Cancer
  • Neoplasms, Endometrial
04

In context

Endometrial Neoplasms Reclassified

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

This study's enrollment of 27 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.

Browse Endometrial Neoplasms studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Endometrial Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have recurrent or persistent endometrial adenocarcinoma, which is to curative therapy or established treatments.
  • Patients must have .
  • Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma.
  • Patients must have signed an approved .
  • Patients of must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of during the study and for at least 3 months following the last dose of Pemetrexed.
  • Patients must discontinue nonsteroidal anti-inflammatory (NSAIDs) medications 2-5 days prior to and for 1-2 days after receiving Pemetrexed, depending on the half-life of the NSAIDs treatment.
  • Patients must agree to this schedule in conjunction with every dose of Pemetrexed.
  • Patients must receive 350-1000 mcg of folic acid (e.g. one prenatal vitamin) starting 7 days prior to the first treatment with Pemetrexed.
  • Patients must be able to ingest 350-1000 mcg of folic acid daily until 3 weeks after the last dose of Pemetrexed.
  • Patients must receive 4 mg Dexamethasone by mouth twice daily, 1 day prior to the dose, the day of and the day after every dose of Pemetrexed.
  • Patients must receive a 1000 mcg vitamin B12 injection 7 days prior to receiving the first treatment with Pemetrexed.
  • Patients must agree to receive 1000 mcg vitamin B12 injection every 9 weeks until 3 weeks after the last dose of Pemetrexed.

Exclusion criteria

Exclusion Criteria:

  • Patients who have had prior therapy with Pemetrexed
  • Patients who have received radiation to more than 25% of marrow bearing areas
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Pemetrexed

    Drug: pemetrexed

Interventions

  • 900 mg/m2, intravenous (IV), every 21 days, until disease progression

    Also known as: LY231514, Alimta

07

What researchers measure

Primary outcomes

  1. Tumor Response

    Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.

    Time frame: baseline to measured progressive disease (up to 24 months)

Secondary outcomes

  1. Number of Participants With Adverse Events by Grade (Measures of Toxicity)

    Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.

    Time frame: every 21-day cycle (up to 24 months)

08

Results

Posted Aug 24, 2009

Participant flow

Participant flow — Overall Study
MilestonePemetrexed
Started27
Completed26
Not completed1
Withdrew: Ineligible (prior radiation)1

Outcome measures

PrimaryTumor Response

Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment. Complete response (CR) = disappearance of all target lesions; Partial response (PR) = 30% decrease in the sum of the longest diameter of target lesions; Progressive disease (PD) = 20% increase in the sum of the longest diameter of target lesions; Stable disease (SD) = small changes that do not meet above criteria.

Time frame:
baseline to measured progressive disease (up to 24 months)
Reported as:
Number · participants
Tumor Response
participantsPemetrexed
Completed Response0
Partial Response1
Stable Disease12
Progressive Disease11
Inevaluable2
SecondaryNumber of Participants With Adverse Events by Grade (Measures of Toxicity)

Adverse events were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. A grading (severity) scale is provided for each adverse event term. Grades range from 0 (none) to 5 (death). The worst grade event per cycle is reported.

Time frame:
every 21-day cycle (up to 24 months)
Reported as:
Number · participants
Number of Participants With Adverse Events by Grade (Measures of Toxicity)
participantsPemetrexed
Leukopenia - Grade 13
Leukopenia - Grade 24
Leukopenia - Grade 38
Leukopenia - Grade 42
Thrombocytopenia - Grade 17
Thrombocytopenia - Grade 21
Thrombocytopenia - Grade 34
Thrombocytopenia - Grade 40
Neutropenia - Grade 12
Neutropenia - Grade 23
Neutropenia - Grade 39
Neutropenia - Grade 43
Anemia - Grade 19
Anemia - Grade 211
Anemia - Grade 35
Anemia - Grade 40
Coagulation - Grade 10
Coagulation - Grade 20
Coagulation - Grade 31
Coagulation - Grade 40
Nausea/vomiting - Grade 15
Nausea/vomiting - Grade 22
Nausea/vomiting - Grade 32
Nausea/vomiting - Grade 40
Gastrointestinal - Grade 16
Gastrointestinal - Grade 26
Gastrointestinal - Grade 33
Gastrointestinal - Grade 40
Alopecia - Grade 11
Alopecia - Grade 20
Dermatologic - Grade 14
Dermatologic - Grade 22
Dermatologic - Grade 31
Dermatologic - Grade 40
Alkaline phosphatase - Grade 14
Alkaline phosphatase - Grade 20
Alkaline phosphatase - Grade 30
Alkaline phosphatase - Grade 40
Serum glutamic-oxaloacetic transaminase - Grade 13
Serum glutamic-oxaloacetic transaminase - Grade 20
Serum glutamic-oxaloacetic transaminase - Grade 30
Serum glutamic-oxaloacetic transaminase - Grade 40
Neurologic - Grade 16
Neurologic - Grade 23
Neurologic - Grade 30
Neurologic - Grade 41
Infection - Grade 10
Infection - Grade 24
Infection - Grade 32
Infection - Grade 40
Pulmonary - Grade 12
Pulmonary - Grade 20
Pulmonary - Grade 30
Pulmonary - Grade 40
Metabolic - Grade 17
Metabolic - Grade 21
Metabolic - Grade 30
Metabolic - Grade 40
Lymphatics - Grade 13
Lymphatics - Grade 20
Lymphatics - Grade 31
Lymphatics - Grade 40
Pain - Grade 13
Pain - Grade 22
Pain - Grade 33
Pain - Grade 40
Constitutional - Grade 14
Constitutional - Grade 28
Constitutional - Grade 35
Constitutional - Grade 40
Renal - Grade 11
Renal - Grade 20
Renal - Grade 30
Renal - Grade 40
Musculoskeletal - Grade 11
Musculoskeletal - Grade 21
Musculoskeletal - Grade 30
Musculoskeletal - Grade 40
Ocular - Grade 12
Ocular - Grade 21
Ocular - Grade 30
Ocular - Grade 40
Cardiovascular - Grade 11
Cardiovascular - Grade 21
Cardiovascular - Grade 30
Cardiovascular - Grade 40
Vascular - Grade 10
Vascular - Grade 20
Vascular - Grade 31
Vascular - Grade 40
Endocrine - Grade 10
Endocrine - Grade 21
Endocrine - Grade 30
Endocrine - Grade 40

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pemetrexed—6/26 (23.1%)26/26 (100%)
Most frequent serious events
Most frequent serious events
EventPemetrexed
AnaemiaBlood and lymphatic system disorders2/26
Febrile neutropeniaBlood and lymphatic system disorders1/26
ThrombocytopeniaBlood and lymphatic system disorders1/26
Gastrointestinal fistulaGastrointestinal disorders1/26
DehydrationMetabolism and nutrition disorders1/26
Muscular weaknessMusculoskeletal and connective tissue disorders1/26
AtaxiaNervous system disorders1/26
SyncopeNervous system disorders1/26
Renal failure acuteRenal and urinary disorders1/26
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPemetrexed
AnemiaBlood and lymphatic system disorders25/26
LeukopeniaBlood and lymphatic system disorders17/26
NeutropeniaBlood and lymphatic system disorders17/26
ConstitutionalGeneral disorders17/26
GastrointestinalGastrointestinal disorders15/26
ThrombocytopeniaBlood and lymphatic system disorders12/26
NeurologicNervous system disorders10/26
Nausea/vomitingGastrointestinal disorders9/26
PainGeneral disorders8/26
MetabolicMetabolism and nutrition disorders8/26

Baseline characteristics

Age, Customized
Age, Customized(participants)Pemetrexed
40-49 years3
50-59 years6
60-69 years10
>69 years7
Sex: Female, Male
Sex: Female, Male(Participants)Pemetrexed
Female26
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pemetrexed
White22
Black3
Asian1
Region of Enrollment
Region of Enrollment(participants)Pemetrexed
United States26
Grade (Histology)
Grade (Histology)(participants)Pemetrexed
G1 - Well-Differentiated5
G2 - Moderately Differentiated8
G3 - Poorly Differentiated13
Gynecologic Oncology Group (GOG) Performance Status
Gynecologic Oncology Group (GOG) Performance Status(participants)Pemetrexed
0 - Fully active14
1 - Ambulatory, Restricted Strenuous Activity12
Prior Treatment
Prior Treatment(participants)Pemetrexed
Prior Chemotherapy26
No Prior Chemotherapy0
Prior Radiotherapy12
No Prior Radiotherapy14
09

Study locations

1 site
  • Gynecologic Oncology Group 215-854-0770
    Philadelphia, Pennsylvania 19103, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Oct 2007 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2006
First posted
Sep 18, 2006
Start
Sep 2006
Primary completionActual
Oct 2007
CompletionActual
Sep 2008
Results first posted
Aug 24, 2009
Last update
Nov 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00377520
First posted
Sep 18, 2006
Start date
Sep 2006
Primary completion
Oct 2007
Completion
Sep 2008
Results posted
Aug 24, 2009
Last update
Nov 20, 2009

Study contacts

David Miller, MD
study chair · Gynecologic Oncology Group

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemetrexed

Start the discussion